Document is current
Any future updates will be listed below
-
Authors
Tsimberidou, Apostolia-Maria http://orcid.org/0000-0003-2713-233X
Skliris, Antonis
Valentine, Alan
Shaw, Jamie
Hering, Ursula
Vo, Henry Hiep
Chan, Tung On
Armen, Roger S.
Cottrell, Jeffrey R.
Pan, Jen Q.
Tsichlis, Philip N.
-
Funding
Funding for this research was provided by:
National Institutes of Health/National Cancer Institute (R01CAN186729 to Philip N. Tsichlis (Ohio State University), P30 CA016672 (The University of Texas MD Anderson Cancer Center), P30 CA016058 (Ohio State University))
This work was also supported in part by donor funds from Mr. and Mrs. Steven McKenzie, Mr. and Mrs. Zane W. Arrott, and Jamie’s Hope for Dr. Tsimberidou’s Personalized Medicine Program.
- License Information
-
More Information
Article History
Received: 11 January 2022
Accepted: 18 April 2022
First Online: 7 May 2022
Declarations
:
: Not applicable.
: Not applicable.
: The authors have the following financial relationships to disclose:Apostolia M. Tsimberidou: Clinical Trial Research Funding (received through the institution): OBI Pharma, IMMATICS, Parker Institute for Cancer Immunotherapy, Agenus, Tempus, Tvardi, Boston Biomedical, Karus Therapeutics; Consulting or Advisory Role: Vincerx, Diaccurate.Alan Valentine: Common stock in Merck and Co.Jamie Shaw is an employee of EMD Serono. Inc. (a business of Merck KGaA, Darmstadt, Germany).Ursula Hering is an employee of Merck KGaA, Darmstadt, Germany.Drs. Skliris, Vo, Chan, Armen, Cottrell, and Pen declare no relevant conflict of interests.
